S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
The 3-Stock Retirement Blueprint (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
The 3-Stock Retirement Blueprint (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
The 3-Stock Retirement Blueprint (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
The 3-Stock Retirement Blueprint (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
The 3-Stock Retirement Blueprint (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
The 3-Stock Retirement Blueprint (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
The 3-Stock Retirement Blueprint (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
The 3-Stock Retirement Blueprint (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
The 3-Stock Retirement Blueprint (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
The 3-Stock Retirement Blueprint (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
The 3-Stock Retirement Blueprint (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
The 3-Stock Retirement Blueprint (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
NASDAQ:CVET

Covetrus - CVET Stock Forecast, Price & News

$20.99
0.00 (0.00%)
(As of 11/2/2022)
Add
Compare
Today's Range
$20.99
$20.99
50-Day Range
$20.85
$20.99
52-Week Range
$13.39
$21.20
Volume
3 shs
Average Volume
1.34 million shs
Market Capitalization
$2.94 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.00

Covetrus MarketRank™ Forecast

Analyst Rating
Hold
1.83 Rating Score
Upside/​Downside
4.7% Downside
$20.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
20.24%
From $0.84 to $1.01 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.20 out of 5 stars

Computer And Technology Sector

620th out of 632 stocks

Drug Stores & Proprietary Stores Industry

6th out of 6 stocks

CVET stock logo

About Covetrus (NASDAQ:CVET) Stock

Covetrus, Inc., together with its subsidiaries, operates as an animal-health technology and services company. It engages in the sale of animal-health consumable products, including proprietary and Covetrus branded products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, parasiticides, and vitamins and supplements to wholesale and retail customers. The company also offers value-added solutions, such as inventory management and e-commerce, as well as continuing education services for practitioners. In addition, it provides practice management software, data-driven applications, client communications tools, and related services to increase staff efficiency and enhance business health; and solutions that integrate with its software platforms, including client communication services, reminders, data backup services, hardware sales and support, and credit card processing services for veterinary practitioners and animal-health clinics. Further, the company engages in the distribution of finished goods pharmacy and specialty pharmaceutical compounding products, as well as offers shipping, manufacturer incentives, service fees, and data integration and support services. It serves animal-health and veterinary practices, and clinics in the companion-animal, equine, and large-animal markets primarily in North America, Europe, and the Asia Pacific. The company was formerly known as HS Spinco, Inc. Covetrus, Inc. was incorporated in 2018 and is headquartered in Portland, Maine. As of October 13, 2022, Covetrus, Inc. was taken private.

Receive CVET Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Covetrus and its competitors with MarketBeat's FREE daily newsletter.

CVET Stock News Headlines

Brokerages Set Covetrus, Inc. (NASDAQ:CVET) Price Target at $20.00
Covetrus, Inc. (CVET)
Covetrus Names Michelle Bonfilio as Chief People Officer
Covetrus Names Margie B. Pritchard General Counsel
Covetrus Announces Retirement of Matthew Foulston
Form PRER14A COVETRUS, INC. - StreetInsider.com
See More Headlines
Receive CVET Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Covetrus and its competitors with MarketBeat's FREE daily newsletter.

CVET Company Calendar

Last Earnings
2/28/2021
Today
11/30/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Drug Stores & Proprietary Stores
Sub-Industry
N/A
Current Symbol
NASDAQ:CVET
Fax
N/A
Employees
5,710
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$20.00
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$16.00
Forecasted Upside/Downside
-4.7%
Consensus Rating
Hold
Rating Score (0-4)
1.83
Research Coverage
6 Analysts

Profitability

Net Income
$-54,000,000.00
Pretax Margin
-0.56%

Debt

Sales & Book Value

Annual Sales
$4.58 billion
Cash Flow
$2.19 per share
Book Value
$10.97 per share

Miscellaneous

Free Float
139,563,000
Market Cap
$2.94 billion
Optionable
Not Optionable
Beta
1.51

Key Executives

  • Mr. Benjamin WolinMr. Benjamin Wolin (Age 46)
    Pres, CEO & Director
    Comp: $1.02M
  • Mr. Matthew J. Foulston (Age 57)
    Exec. VP & Global CFO
    Comp: $624.66k
  • Ms. Georgina Wraight (Age 47)
    Exec. VP & Pres of Global Technology Solutions
    Comp: $563.4k
  • Mr. Matthew Malenfant (Age 60)
    Chief Commercial Officer
    Comp: $533.62k
  • Ms. Rebecca Kidd (Age 53)
    Head of Operations & Operational Excellence
  • Mr. Andrew B. Coxhead (Age 53)
    VP, Corp. Controller & Chief Accounting Officer
  • Mr. Nicholas Michael Jansen
    VP of Investor Relations
  • Ms. Margie B. Pritchard
    Gen. Counsel & Corp. Sec.
  • Mr. Cameron R. Foster
    Sr. VP of Strategy & Corp. Devel.
  • Ms. Michelle Bonfilio (Age 51)
    Chief People Officer













CVET Stock - Frequently Asked Questions

Should I buy or sell Covetrus stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Covetrus in the last twelve months. There are currently 1 sell rating and 5 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CVET shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CVET, but not buy additional shares or sell existing shares.
View CVET analyst ratings
or view top-rated stocks.

What is Covetrus' stock price forecast for 2023?

6 brokers have issued 1-year price targets for Covetrus' shares. Their CVET share price forecasts range from $16.00 to $22.00. On average, they anticipate the company's share price to reach $20.00 in the next twelve months. This suggests that the stock has a possible downside of 4.7%.
View analysts price targets for CVET
or view top-rated stocks among Wall Street analysts.

How have CVET shares performed in 2022?

Covetrus' stock was trading at $19.97 at the beginning of the year. Since then, CVET stock has increased by 5.1% and is now trading at $20.99.
View the best growth stocks for 2022 here
.

How were Covetrus' earnings last quarter?

Covetrus, Inc. (NASDAQ:CVET) announced its quarterly earnings data on Sunday, February, 28th. The company reported $0.21 EPS for the quarter, topping analysts' consensus estimates of $0.16 by $0.05. The business earned $1.12 billion during the quarter, compared to analysts' expectations of $1.06 billion. Covetrus had a negative net margin of 0.28% and a positive trailing twelve-month return on equity of 6.83%. The company's revenue for the quarter was up 11.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.18 earnings per share.

What is Benjamin Wolin's approval rating as Covetrus' CEO?

25 employees have rated Covetrus Chief Executive Officer Benjamin Wolin on Glassdoor.com. Benjamin Wolin has an approval rating of 89% among the company's employees.

What other stocks do shareholders of Covetrus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Covetrus investors own include Pfizer (PFE), NVIDIA (NVDA), Advanced Micro Devices (AMD), AT&T (T), Activision Blizzard (ATVI), Boeing (BA), Chegg (CHGG), Enphase Energy (ENPH), Enterprise Products Partners (EPD) and Livongo Health (LVGO).

What is Covetrus' stock symbol?

Covetrus trades on the NASDAQ under the ticker symbol "CVET."

Who are Covetrus' major shareholders?

Covetrus' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (11.85%), Vanguard Group Inc. (8.48%), State Street Corp (2.81%), Glazer Capital LLC (2.48%), Pentwater Capital Management LP (2.22%) and UBS Group AG (2.10%). Insiders that own company stock include Anthony C Jr Providenti, Benjamin Wolin, David Stuart Hinton, Dustin Finer, Edward Mcnamara, Georgina Wraight, Herbert Virgin, Laura J Phillips, Michael Ellis and Timothy Ludlow.
View institutional ownership trends
.

How do I buy shares of Covetrus?

Shares of CVET stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Covetrus' stock price today?

One share of CVET stock can currently be purchased for approximately $20.99.

How much money does Covetrus make?

Covetrus (NASDAQ:CVET) has a market capitalization of $2.94 billion and generates $4.58 billion in revenue each year. The company earns $-54,000,000.00 in net income (profit) each year or ($0.10) on an earnings per share basis.

How many employees does Covetrus have?

The company employs 5,710 workers across the globe.

How can I contact Covetrus?

Covetrus' mailing address is 7 CUSTOM HOUSE STREET, PORTLAND ME, 04101. The official website for the company is www.henryscheinvet.com. The company can be reached via phone at (888) 280-2221 or via email at nicholas.jansen@covetrus.com.

This page (NASDAQ:CVET) was last updated on 12/1/2022 by MarketBeat.com Staff